On Thursday, Novartis (NYSE: NVS) won a reprieve from the U.S. Supreme Court after it put on hold the cancellation of some of Novartis' patents on the dosage regimen for its multiple sclerosis drug Gilenya, according to a report from Bloomberg Law. The U.S. Supreme Court's Chief Justice John Roberts put a stay on the mandate from the US Court of Appeals for the Federal Circuit, which had ruled that many of Novartis's patent claims were invalid regarding Gilenya. This ruling opened the gates for generic drug makers to sell copies of the drug.
https://www.tipranks.com/news/novartis-nyse-nvs-wins-reprieve-from-u-s-supreme-court-regarding-gilenya?utm_source=advfn.com&utm_medium=referral
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Dez 2022 até Jan 2023 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Jan 2022 até Jan 2023 Click aqui para mais gráficos Novartis.